Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03256773 · ClinicalTrials.gov registry record
High Resolution Micro OCT Imaging
A clinical trial of COVID-19 and Cystic Fibrosis, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT03256773: Active study of COVID-19 and Cystic Fibrosis, sponsored by University of Alabama at Birmingham.
NCT03256773 is a study of COVID-19 and Cystic Fibrosis that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 60 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03256773, a study of COVID-19 and Cystic Fibrosis, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.
Primary Outcome
to determine if a uOCT probe can image airway epithelial cells from the lung and the nares of adult patients
Conditions Studied
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-04-15 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT03256773 still lists
NCT03256773 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 5 conditions, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT03256773 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT03256773 about?
NCT03256773 is a clinical study titled "High Resolution Micro OCT Imaging". The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.
What is the current status of trial NCT03256773?
This trial is currently active not recruiting. The enrollment target is 60 participants. The study started on 2016-04-15. Estimated completion is 2026-12-31.
What conditions does trial NCT03256773 study?
This clinical trial studies the following conditions: COVID-19, Cystic Fibrosis, COPD, Sinusitis, PCD - Primary Ciliary Dyskinesia.
Who is sponsoring clinical trial NCT03256773?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03256773 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03256773's enrollment target sits among peer trials
60 233rd of 298 higher than 60 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI